Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
about
Invariant NKT cells as novel targets for immunotherapy in solid tumorsAntitumor Responses of Invariant Natural Killer T CellsCD1d- and MR1-Restricted T Cells in SepsisAdoptive T Cell Therapy Targeting CD1 and MR1The regulatory role of invariant NKT cells in tumor immunityiNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potencyBioinformatics multivariate analysis determined a set of phase-specific biomarker candidates in a novel mouse model for viral myocarditis.Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maNKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1Recognition of lipid antigens by T cells.Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvementAnti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humansInvariant NKT cells increase drug-induced osteosarcoma cell death.NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells.Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.NKT cell costimulation: experimental progress and therapeutic promiseThe adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation.Roles of CD1d-restricted NKT cells in the intestine.Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophagesAdoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasmsMedulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cellsHarnessing human CD1d restricted T cells for tumor immunity: progress and challenges.Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.NKT cells in mucosal immunity.Targeting natural killer cells and natural killer T cells in cancer.Natural killer T cell based Immunotherapy.Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in miceNatural killer T cells in liver injury, inflammation and cancer.A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.
P2860
Q21284987-82F65F4D-E2DE-4DBA-999B-CC78869CE167Q26778648-DDC068D1-4E78-45D9-A2BA-5841D7434B56Q26796132-0186F866-EDAF-41D5-A398-9FC756A0F401Q26998503-DD235162-BD1A-4D85-9BCB-2D0093974DE8Q27023425-74B8A171-1E9A-4A7E-9A77-F2D46F2CBB8EQ33523809-89807C9D-EAF2-446A-9685-833E16B71A92Q33622444-9CA96E83-33AE-4F6B-8C55-C5D2EE556BBBQ33939552-EFE387DD-6F4E-45C1-BDD9-863BCA058B39Q34257912-1101DA74-B45A-4E1A-84B0-D47B882732D6Q34338958-E609CD5E-B88F-461F-8458-323825A07CC7Q35096144-A7057ED4-AE63-4530-A271-323BAFF6838CQ35127172-1668EF6F-5F37-4B68-BC39-DBED3FD6EAB0Q35136030-9B1D30BB-A375-42AE-890F-DAC14F155E6BQ35506478-9DAB488B-51EE-4F15-805E-6401B8A4DEE1Q35605318-55E8388F-283B-4635-8B95-4665E203E295Q35956535-291D27E0-D499-4993-9D39-C1C8076E9E38Q35990678-B1A348E3-68A8-4D4E-9ACD-53F49CD0A561Q36012693-3F30C5F7-8AC3-41F2-B52B-E7C46E75B6FCQ36146922-9B8D2CB5-CB1C-48BA-BA16-5227786EC949Q36177081-7D40FF2C-EF9A-46BB-915A-48DE6E9EBB23Q36239694-C2B27C62-B574-4C17-908A-C2F066EE89F4Q36446525-8FA23DA4-BE4D-4B23-AFB6-CD1838B94245Q36568780-7A4E5743-B3B2-410E-9F10-976C46F49184Q36570136-46ADCC02-0E5A-4278-96FB-191E39EB7C15Q36713547-76FC44D8-D4CA-4146-B835-EB17A18A4500Q36739843-2DD220A3-5D40-4645-81DD-DE6ABE9BF1FEQ36797263-DA20BD9F-923C-4B36-BD3B-010BFCD961FAQ36809882-138581D9-E1DA-4E61-8A0C-27A99F6EA377Q37121488-ED6A1997-741B-4E62-AE85-4C6F84FCD162Q37209184-F796E2F3-6D77-4E95-A6AE-0910E8D82FDFQ37246757-C530B9B9-C20C-4032-B08A-685B6BF1A447Q37257512-96AF74DB-ED16-47FE-9AF7-284D541C22B8Q37388427-339256F5-5606-414E-84F7-657D4A335C8BQ37426935-25529321-2CB9-4F54-B761-5D27A3C9C1F1Q37545348-832A2736-76B5-47AD-9A7F-469587B0D547Q37995950-97899AFE-8727-4FAD-9F56-316CF91BB4E4Q38148759-D07A1E43-D1B3-4D93-B33E-E0DCCD5BEB44Q38338690-82FCFAB1-5564-4224-A1EE-F08D28C44EFAQ38525797-90967A36-FA3E-4BE6-A191-EA8B82C6C155Q38634685-E82A2347-1F7F-4892-85D1-036A1A8916CC
P2860
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@en
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@nl
type
label
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@en
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@nl
prefLabel
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@en
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@nl
P2093
P2860
P356
P1433
P1476
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
@en
P2093
Metelitsa LS
Weinberg KI
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402943
P577
2003-06-01T00:00:00Z